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recognize this specific problem. We
are deeply worried that we are not
the only ones to observe this sad expe-
rience: A case reported in Germany led
to an unusual procedure and finally re-
sulted in a transplant.7,8 Another simi-
lar observation was made in the United
States after implantation of the device
and led to correspondence with us:
‘‘I read with great interest your report
of 7 patients with bad outcomes after
placement of the Shelhigh stentless
valve-conduit. We have had recent ex-
perience with a man who experienced
valve failure 3 years after placement
of one Shelhigh conduit. A false aneu-
rysm and extensive inflammation were
found at surgery (the surgeon said he
thought there may be an abscess),
and the entire prosthesis had to be re-
moved and replaced with a homograft.
Cultures for bacteria only were nega-
tive. The patient did well postopera-
tively and was discharged on day
17 postoperatively. Our pathologists
also analyzed the tissue and found
extensive acute and chronic inflamma-
tion. On special staining, the wall of
the conduit was infiltrated with numer-
ous acid fast bacteria. Unfortunately,
we did not culture for acid fast organ-
isms so we were not be able to identify
what it is.’’ (P. O’Keefe, Loyola
University Medical Center, personal
communication).
We urge Dr Gabbay not to fight
against reports regarding the NR-
2000C but to encourage him to
shed light on those cases and to rec-
ognize that we had made several at-
tempts to warn him not only about
the aortic valved conduit but also
about several other devices that we
found to give unsatisfactory results
(e.g. the pulmonary conduit and the
bovine IMA).
Thierry Carrel, MDa
Florian S. Schoenhoff, MDa
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Letters to the Editor
The JournaSHELHIGH BIOPROSTHESIS IN
ACTIVE INFECTIVE
ENDOCARDITIS
To the Editor:
A recent article by Carrel and col-
leagues1 deals with the deleterious
outcome of patients who received
No-React (Shelhigh, Inc, Union,
NJ)–treated stentless valved conduits.
Seven (6.1%) of 115 patients pre-
sented with sudden disastrous find-
ings at the level of the aortic root,
and 4 of them underwent emergency
operations because of disintegration
of the graft along with rupture of the
aortic root. The authors reported thatl of Thoracic and Cardiovascular Surgeretrospectively the main findings
were persistent fever or subfebrility
over months. They conclude that the
use of the Shelhigh aortic stentless
prosthesis can no longer be advo-
cated. Is it possible that the authors
have overlooked the patients’ clinical
condition of persisting postoperative
fever, which can lead to the severe
prosthetic endocarditis described in
their article?
We previously reported very good
clinical results from our center using
the above products, especially in pa-
tients with severe active infective
endocarditis. The device was tested
with satisfactory results, and prelimi-
nary follow-up data were published
in 2003 and 2005.2,3 Recent publica-
tions in 2006 and 2008 have shown
satisfactory early and midterm results
with a low reinfection rate in patients
with native or prosthetic endocarditis
complicated by paravalvular abscess,
and the hemodynamic function of the
implants in the aortic position was
comparable with that of homografts.4,5
These articles have perhaps been over-
looked by Carrel and colleagues.
From February 2000 until July
2008, 319 Shelhigh No-React–treated
stentless valves have been implanted
in 305 patients in our institution. Of
these, 17 (5.5%) patients required re-
operations because of reinfection.
The 30-day and 1-, 3-, and 5-year rates
for freedom from reoperation caused
by reinfection were 100%, 94.4% 
1.8%, 87.0%  3.2%, and 83.8% 
4.4%, respectively.4
Analysis of reoperation because of
valve-related complications showed
12 patients who underwent reopera-
tions because of paravalvular leakage,
which is mainly related to endocardi-
tis. The freedom from reoperation be-
cause of valve-related complications
is shown in Figure 1: the 30-day and
1- and 5-year freedom from reopera-
tion rates were 98.9%  0.7%,
97.9%  8.4%, and 92.3%  2.3%,
respectively.
Thus, in our series, there was no
patient who required reoperation, asry c Volume 137, Number 5 1295
term results regarding handling of the
prosthesis and postoperative hemody-
namics.4 The positive experience de-
scribed by the Berlin group was one
of the reasons we hesitated to attribute
the catastrophic outcome in several of
our patients to the prosthesis itself.
However, there are 2 major differences
in the patient population reported by
the Berlin group and ours.
First, the authors from Berlin might
have overlooked the fact that, unlike in
their series, the majority of our patients
who received the NR2000-C prosthe-
sis did not have endocarditis at the
time of the initial operation. Our pa-
tients had subfebrile temperatures
during weeks or months after elective
operations for aortic root dilation, indi-
cating that failure of the device might
have mimicked destructive endocardi-
tis. We are wondering whether Dr
Letters to the EditorFIGURE 1. Freedom from reoperation because of valve-related events after Shelhigh implantation
(n ¼ 305 patients): Deutsches Herzzentrum Berlin, February 2000 to July 2008.Reply to the Editor:
We thankDrsMusci, Siniawski, and
Hetzer for their comments regarding
our recent article entitled ‘‘Deleterious
outcome of No-React treated stentless
valved conduits following aortic root
replacement.’’1 We appreciate their
scientific approach to the problem and
congratulate the authors on their excel-
lent results obtained in patientswith ac-
tive infective endocarditis.
The authors refer to 2 of their articles
published in 20032 and 2005,3 which
both have been cited in our article. As
already said, we originally believed
that the Shelhigh aortic valve conduit
(Shelhigh, Inc, Union, NJ) was an at-
tractive alternative to homografts. We
published our preliminary experience
soon after the prosthesis was intro-
duced and showed excellent short-
Hetzer’s group is able to differentiate
between reinfection caused by a recur-
rent endocarditis and failure of the de-
vice in all of their cases.
Second, most data presented by Dr
Musci primarily focuses on the Shel-
high Stentless aortic valve and not on
the Shelhigh aortic valved conduit. In
their article published in 2005,3 they
report on 327 patients who underwent
surgical intervention for endocarditis
between 1996 and 2003. Only 4
(1.2%) patients in this group received
the NR-2000C conduit. In the latest re-
port,5 with an impressive 1077 pa-
tients, the percentage of patients who
received the Shelhigh NR-2000C con-
duit increased to 2.4%. Therefore the
total number of implanted Shelhigh
aortic valved conduits is 26 in Berlin
compared with 115 in Berne. More-
over, the authors do not provide sepa-
rate data for the NR-2000C, and
previous experiences from a joint
multicenter study showed that the
rate of echocardiographic follow-up
was very low in this institution.
The most recent case of a severe
problem with a Shelhigh conduit was
observed at Johns Hopkins University,
and the operation was performed by
Duke Cameron. The young patientdescribed in the article by Carrel and
colleagues.1 In contrast, we were able
to document good outcomes of the
treated patients and did not find that
the Shelhigh products were associated
with ‘‘deleterious outcome.’’
Michele Musci, MD
Henryk Siniawski, MD, PhD
Roland Hetzer, MD, PhD
Department of Cardiothoracic and
Vascular Surgery
Deutsches Herzzentrum Berlin
Berlin, Germany
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